DrugDashboards
← Home
Company profile

Mylan Laboratories Limited

Everything our data knows about this company's US footprint — the products it puts its name on, how many are in short supply or under recall right now, and where it makes them. A “labeler” is whoever's name is on the package; that can be the maker, a repackager, or a distributor.

3
products (NDCs) it labels
3
distinct drugs
0
of its products in shortage now
0
Class I/II recalls, past 12 months

Financials — VIATRIS INC.

From the parent company's audited SEC 10-K filings (ticker VTRS). This labeler may be one subsidiary of the filer; figures are company-wide.

$14.3B
Revenue, FY2025
$1.0B
R&D spend
Net income
$0.5B
Returned to shareholders
R&D vs. shareholder returns, by year
18
19
20
21
22
23
24
25
R&D Buybacks + dividends
ⓘ How this was built
Data sources
  • SEC EDGAR XBRL company facts — VIATRIS INC. audited 10-K filings
Method

Figures are the filer's own reported us-gaap facts per fiscal year: revenue, R&D expense, net income, and cash paid for buybacks plus dividends. Restatements replace originals (latest filing wins). The labeler on this page is matched to its SEC parent by name pattern; no match would mean no panel, never a guess.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Its products in short supply now

None of this company's products are on the FDA shortage list right now.

Sources:product counts from the FDA NDC Directory; shortages from the FDA drug-shortage list and recalls from FDA enforcement reports, both matched to this company's NDCs; manufacturing countries from DailyMed labels joined to FDA establishment registrations. Educational only.